
Senti Bio (NASDAQ: SNTI) Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia SOUTH SAN FRANCISCO, Calif., July 01, 2024 — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti […]